Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cidofovir

A P Lea1, H M Bryson

  • 1Adis International Limited, Auckland, New Zealand.

Drugs
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

Cidofovir, an antiviral, effectively treats cytomegalovirus (CMV) retinitis in AIDS patients. Administered weekly or bi-weekly with probenecid and hydration, it delays disease progression and has no documented resistance in patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Azithromycin. A pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital Chlamydia trachomatis infections in women.

PharmacoEconomics·1997
Same author

Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Drugs·1997
Same author

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.

Drugs·1997
Same author

Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.

Drugs·1997
Same author

Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.

Drugs·1997
Same author

Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.

Drugs·1997
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Virology and Pharmacology
  • Antiviral drug development
  • Ophthalmology

Background:

  • Human cytomegalovirus (CMV) infection is a significant opportunistic infection, particularly in immunocompromised individuals.
  • CMV retinitis can lead to vision loss if left untreated.
  • Cidofovir is a nucleotide analogue with demonstrated antiviral activity.

Purpose of the Study:

  • To evaluate the efficacy of cidofovir in treating CMV retinitis.
  • To assess the optimal dosing regimen for cidofovir therapy.
  • To investigate the potential for viral resistance to cidofovir.

Main Methods:

  • Cidofovir is a nucleotide analogue administered intravenously.
  • It is phosphorylated intracellularly to its active form, inhibiting viral DNA polymerase.

Related Experiment Videos

  • Therapy involves weekly induction and bi-weekly maintenance dosing, with co-administration of probenecid and saline hydration to mitigate nephrotoxicity.

    • Main Results:

    • Immediate cidofovir therapy significantly delayed CMV retinitis progression compared to deferred treatment in patients with Acquired Immunodeficiency Syndrome (AIDS).
    • Cidofovir also demonstrated efficacy in delaying progression of CMV retinitis relapses after prior treatments.
    • While in vitro studies show potential for resistance, no viral resistance has been documented in patients treated with cidofovir to date.

    Conclusions:

    • Cidofovir is an effective treatment for CMV retinitis, particularly in patients with AIDS.
    • Its long intracellular half-life allows for convenient dosing schedules.
    • Careful administration with probenecid and hydration is crucial to prevent nephrotoxicity, and resistance has not been observed clinically.